Since we determined the profound pro-metastatic properties of EP4 in pancreatic cancer, we speculated that the combining of our novel EP4 antagonist L001 and gemcitabine might offer a more effective therapeutic regimen for metastatic pancreatic cancer. Here, PTGER4 is linked to familial pancreatic carcinoma.